EUCTR2016-002732-32-IT进行中（未招募）1 期
Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): efficacy and toxicity evaluation - LU-PSMA
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS0 个研究点目标入组 210 人开始时间: 2019年9月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patients must have histologically or cytologically confirmed prostate cancer
- •2. Male, aged = 18 years.
- •3. Metastatic castration resistant prostate cancer
- •4. 68Ga-PSMA PET/CT positive in known site of disease, documented by CT or MRI or bone scan or 18Coline-PET
- •5. Patients with clinical progression from previous treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1. Patients treated with chemotherapy and 223Ra radiotherapy within 4 weeks and treated within 2 weeks with palliative radiotherapy.
- •2. ECOG performance status >2
- •3. Assessed bone marrow invasion > 50%
研究者
相似试验
已完成
1 期
An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)ACTRN12618001073291St Vincent's Hospital Sydney56
进行中（未招募）
2 期
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:CancerNCT05867615Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS83
已完成
1 期
Radionuclide therapy using 177Lu-PSMA: a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)castrate-resistant prostate cancerACTRN12618001552279St Vincent's Hospital15
已完成
2 期
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)Metastatic Castration Resistant Prostate Cancer68Ga-PSMA PET/CT PositiveNCT03454750Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori143
招募中
1 期
[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) in patients with prostate cancer and biochemical but not radiomorphologic local recurrence after primary therapy with curative intention: a future planned phase II studyProstate cancerEUCTR2022-003713-11-ATMedical University of Vienna20